145 results on '"Lockhart, Albert C."'
Search Results
2. Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies
3. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study
4. Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
5. Data from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
6. The soluble guanylyl cyclase pathway is inhibited to evade androgen deprivation-induced senescence and enable progression to castration resistance
7. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression
8. Figure S5 from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
9. Supplementary Methods from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
10. Phosphorylation of IRAK4 is present in early-passage patient-derived cell lines and independent pancreatic tissue microarray from Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
11. Supplementary Tables from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
12. Supplementary Data from First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
13. IRAK1 and/or IRAK4 knockdown sensitizes PDAC cells to chemotherapeutics. from Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
14. Detailed description of materials, method; and supplementary figure legends from Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
15. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
16. Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers
17. Additional file 2 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
18. Additional file 1 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
19. Additional file 3 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
20. Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)
21. Phase I Pharmacokinetic Study of Single Agent Trametinib in Patients With Advanced Cancer and Hepatic Dysfunction
22. HER kinase inhibition in patients with HER2- and HER3-mutant cancers
23. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
24. The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
25. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
26. Abstract 3467: Inhibition of AURKA targets gastrointestinal cancer cells with activated KRAS by inhibiting RPS6KB1
27. Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer
28. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer
29. Abstract CT001: Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study
30. CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.
31. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.
32. Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.
33. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
34. A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).
35. A National Cancer Database analysis of treatment utilization and associated outcomes in elderly patients with locally advanced esophageal cancer.
36. Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.
37. A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.
38. CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.
39. A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
40. Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.
41. Abstract 181: Constitutive IRAK1/4 kinase activation contributes to NF-kB activity and chemoresistance in pancreatic cancer
42. Neoadjuvant chemotherapy versus chemoradiation prior to esophagectomy: Impact on rate of complete pathologic response and survival in esophageal cancer patients.
43. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.
44. Phase I study of X-82, an oral dual anti-VEGFR/PDGFR tyrosine kinase inhibitor, with everolimus in solid tumors.
45. A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT).
46. Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.
47. Investigational NEDD8-activating enzyme inhibitor pevonedistat (Pev) plus chemotherapy in patients (Pts) with solid tumors (Phase 1b study): Antitumor activity of pev plus carboplatin (Carbo)/paclitaxel (Pac).
48. Phase I pharmacokinetic study of single agent trametinib in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study.
49. A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors.
50. A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic adenocarcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.